keyword
https://read.qxmd.com/read/38513509/role-of-adjunctive-cariprazine-for-treatment-resistant-depression-in-patients-with-major-depressive-disorder-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#1
REVIEW
Eman Ali, Fakhar Latif, Yusra Mashkoor, Ayesha Sheikh, Amna Iqbal, Rabia Owais, Jawad Ahmed, Sadiq Naveed, Abdul Moeed, Irfan Ullah, Sanila Mughal
INTRODUCTION: Cariprazine is an orally active dopamine D3-preferring D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, being considered as a treatment for refractory MDD. Therefore, we aim to perform the first meta-analysis of current literature, to collate changes in depression from baseline and assess tolerability of adjunctive cariprazine in MDD populace. METHODS: PubMed, Embase, Google Scholar, ClinicalTrials.Gov, and Cochrane Library were searched from inception till 1st September 2023...
March 11, 2024: Asian Journal of Psychiatry
https://read.qxmd.com/read/38497891/dual-disorder-does-expert-clinical-experience-support-the-rationale-for-cariprazine-use
#2
JOURNAL ARTICLE
J Martinez-Raga, M Bajouco, D Kenzin, J Sahlsten, D De Berardis, G Tzeferakos, E Wagner, G França, J Johnsen, C Roncero, H Grunze
Comorbid substance use disorder (SUD) in patients with schizophrenia (dual disorder, DD) is a frequent occurrence in the psychiatric clinical practice and is positively associated with poorer outcomes. Despite a very high co-prevalence, clinical guidelines for SUD and severe mental illnesses tend to give limited consideration to co-existing disorders regarding diagnosis and management. This article is the result of a meeting held in February 2023 to discuss common challenges and best clinical practice initiatives for patients with schizophrenia and DD in different treatment settings...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38425604/an-awakener-patient-suffering-from-treatment-resistant-depression-following-adjunctive-cariprazine
#3
Konstantinos Bonotis
This report presents a case of particular interest in terms of course and therapeutic outcomes, concerning a patient suffering from treatment-resistant depression in whom adjunctive cariprazine to medication brought about an immediate overall improvement in symptomatology. Informed written consent was obtained from the subject for publication of the case.
January 2024: Curēus
https://read.qxmd.com/read/38406088/personalized-approach-in-the-management-of-difficult-to-treat-and-treatment-resistant-depression-with-second-generation-antipsychotics-a-delphi-statement
#4
JOURNAL ARTICLE
Hansal Bhachech, Kamal Nath, Roop Sidana, Nilesh Shah, Rajesh Nagpal, R Sathianathan, Ashutosh Kakkad, Krishnaprasad Korukonda
Background Major depressive disorder (MDD) has many facets including mixed or atypical depression that requires personalized care to improve treatment-related outcomes. Second-generation antipsychotics (SGAs) offer complementary mechanisms for clinical roles in difficult-to-treat depression and treatment-resistant depression cases. Aim/objective To further delineate a consensus on the clinical positioning of SGAs for MDD, mixed, or atypical depression, a Knowledge Attitude Perception (KAP)-mediated Delphi Statement was planned...
January 2024: Curēus
https://read.qxmd.com/read/38385774/early-onset-of-tardive-dyskinesia-in-an-antipsychotic-naive-patient-treated-with-low-dose-cariprazine
#5
JOURNAL ARTICLE
Konstantinos Tsamakis, Maria Pantazidi, Evangelos Alevyzakis, Dimitrios Tsiptsios, Christoph Mueller, Nikolaos Smyrnis, Emmanouil N Rizos
No abstract text is available yet for this article.
February 19, 2024: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/38370937/cariprazine-augmentation-in-a-patient-with-clozapine-resistant-schizophrenia
#6
JOURNAL ARTICLE
R Dhivya Karoline, Samuvel Sekar, Ss Asha Charitha, Jibi Achamma Jacob
No abstract text is available yet for this article.
November 2023: Industrial Psychiatry Journal
https://read.qxmd.com/read/38367320/adjunctive-cariprazine-as-a-novel-effective-strategy-for-treating-major-depressive-disorder-a-systematic-review-and-meta-analysis
#7
REVIEW
Minjia Xie, Youjia Qiu, Menghan Wang, Xingzhou Wei, Yuchen Tao, Aojie Duan, Jing Shang, Wei Gao, Zhong Wang
BACKGROUND: Cariprazine has been approved by the Food and Drug Administration for treating bipolar depression and as an adjunctive treatment for Major Depressive Disorder (MDD). However, it remains unclear about its pharmacological efficacy in treating MDD. Therefore, a meta-analysis was conducted to investigate the adjunctive use of cariprazine in MDD. METHODS: Electronic databases were searched for eligible studies evaluating the efficacy and safety of cariprazine in patients with MDD up to November 15, 2023...
February 8, 2024: Journal of Psychiatric Research
https://read.qxmd.com/read/38338224/third-generation-antipsychotics-and-lurasidone-in-the-treatment-of-substance-induced-psychoses-a-narrative-review
#8
REVIEW
Valerio Ricci, Domenico De Berardis, Giuseppe Maina
This narrative review explores the efficacy and tolerability of third-generation antipsychotics (TGAs)-aripiprazole, cariprazine, brexpiprazole, and lurasidone-for the management of substance-induced psychosis (SIP). SIP is a psychiatric condition triggered by substance misuse or withdrawal, characterized by unique features distinct from those of primary psychotic disorders. These distinctive features include a heightened prevalence of positive symptoms, such as hallucinations and delusions, in addition to a spectrum of mood and cognitive disturbances...
January 29, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38310714/pharmacodynamic-properties-of-lumateperone-and-its-efficacy-in-acute-bipolar-depression-a-mechanistic-hypothesis-based-on-data
#9
JOURNAL ARTICLE
Konstantinos N Fountoulakis, Mauricio Tohen, Carlos A Zarate
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this condition. The neurobiology of bipolar depression and the possible mechanistic targets of bipolar antidepressant therapy remain elusive. The current study investigated whether the pharmacodynamic properties of lumateperone fit into a previously developed model which was the first to be derived based on the strict combination of clinical and preclinical data...
February 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38308625/a-systematic-review-of-the-real-world-effectiveness-and-economic-and-humanistic-outcomes-of-selected-oral-antipsychotics-among-patients-with-schizophrenia-in-the-united-states-updating-the-evidence-and-gaps
#10
REVIEW
Ki Jin Jeun, Khalid M Kamal, Keyuri Adhikari, David A Nolfi, Md Najeeb Ashraf, Christopher Zacker
BACKGROUND: Schizophrenia is a chronic, relapsing, and burdensome psychiatric disorder affecting approximately 0.25%-0.6% of the US population. Oral antipsychotic treatment (OAT) remains the cornerstone for managing schizophrenia. However, nonadherence and high treatment failure lead to increased disease burden and medical spending. Cost-effective management of schizophrenia requires understanding the value of current therapies to facilitate better planning of management policies while addressing unmet needs...
February 3, 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38308622/impact-of-formulary-related-pharmacy-claim-rejections-of-cariprazine-on-health-care-utilization-and-treatment-patterns-among-patients-with-bipolar-i-disorder
#11
JOURNAL ARTICLE
François Laliberté, Enrico Zanardo, Sean D MacKnight, Ana Urosevic, Sally W Wade, Mousam Parikh
BACKGROUND: Formulary restrictions, intended to limit inappropriate medication use and decrease pharmacy costs, may prevent or delay patients with bipolar I disorder from initiating cariprazine, a dopamine D3 -preferring D3 /D2 and serotonin 5HT1A receptor partial agonist that is approved to treat manic/mixed or depressive episodes associated with bipolar I disorder. Little is known about the downstream consequences of formulary-related cariprazine prescription rejections. OBJECTIVE: To evaluate the impact of formulary-related cariprazine claim rejections on health care resource utilization (HCRU) and treatment patterns among patients newly prescribed cariprazine for bipolar I disorder...
February 3, 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38288838/cariprazine-augmentation-in-treatment-resistant-bipolar-depression-data-from-a-retrospective-observational-study
#12
JOURNAL ARTICLE
Elena Teobaldi, Enrico Pessina, Azzurra Martini, Carlo Ignazio Cattaneo, Domenico De Berardis, Vassilis Martiadis, Giuseppe Maina, Gianluca Rosso
BACKGROUND: Treatment-resistant bipolar depression is one of the leading problems in psychiatry with serious consequences on patients functioning, quality of life and resource utilization. Despite this, there is a lack of consensus on diagnostic criteria and treatment algorithms. OBJECTIVE: The objective of the present study is to assess the acute effectiveness and tolerability of cariprazine in the management of treatment resistant bipolar depression. METHODS: This is a four weeks retrospective multicentric observational study on patients with treatment resistant bipolar depression receiving cariprazine in augmentation to the current treatment...
January 29, 2024: Current Neuropharmacology
https://read.qxmd.com/read/38277187/safety-and-tolerability-of-cariprazine-for-the-adjunctive-treatment-of-major-depressive-disorder-a-pooled-analysis-of-phase-2b-phase-3-clinical-trials
#13
JOURNAL ARTICLE
Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese
To characterize the safety and tolerability of adjunctive cariprazine in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT). Post hoc analyses evaluated pooled data from 2 fixed-dose phase 3 cariprazine studies (1.5 and 3 mg/d [approved doses for MDD]). In a separate safety analysis, cariprazine 0.1-4.5 mg/d was evaluated using data from the 2 fixed-dose trials plus 3 flexible-dose studies grouped by modal-daily dose. In the pooled phase 3 studies (placebo = 503, 1...
January 25, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38250036/morphine-and-foot-shock-responsive-neuronal-ensembles-in-the-vta-possess-different-connectivity-and-biased-gpcr-signaling-pathway
#14
JOURNAL ARTICLE
Fan Wang, Chao-Bao Liu, Yi Wang, Xi-Xi Wang, Yuan-Yao Yang, Chang-You Jiang, Qiu-Min Le, Xing Liu, Lan Ma, Fei-Fei Wang
Background: Neurons in the ventral tegmental area (VTA) are sensitive to stress and their maladaptation have been implicated in the psychiatric disorders such as anxiety and addiction, etc . The cellular properties of the VTA neurons in response to different stressors related to different emotional processing remain to be investigated. Methods: By combining immediate early gene (IEG)-dependent labeling, rabies virus tracing, ensemble-specific transcriptomic analysis and fiber photometry recording in the VTA of male mice, the spatial distribution, brain-wide connectivity and cellular signaling pathways in the VTA neuronal ensembles in response to morphine (Mor-Ens) or foot shock (Shock-Ens) stimuli were investigated...
2024: Theranostics
https://read.qxmd.com/read/38219239/probiotics-for-adults-with-major-depressive-disorder-compared-with-antidepressants-a-systematic-review-and-network-meta-analysis
#15
JOURNAL ARTICLE
Shilin Zhao, Suisha Liang, Jun Tao, Ye Peng, Siqi Chen, Hogan K F Wai, Feng-Ying Chung, Zhen Y Sin, Matthew K L Wong, Andrea M Haqq, Wing C Chang, Michael Y Ni, Francis K L Chan, Siew C Ng, Hein M Tun
CONTEXT: Despite recent advances in antidepressants in treating major depression (MDD), their usage is marred by adverse effects and social stigmas. Probiotics may be an efficacious adjunct or standalone treatment, potentially circumventing the aforementioned issues with antidepressants. However, there is a lack of head-to-head clinical trials between these 2 interventions. OBJECTIVE: A systematic review and network meta-analysis was conducted to compare the efficacy and acceptability of these 2 interventions in treating MDD...
January 14, 2024: Nutrition Reviews
https://read.qxmd.com/read/38170806/rhabdomyolysis-during-adjunctive-treatment-with-cariprazine-in-a-clozapine-resistant-schizophrenia-patient
#16
JOURNAL ARTICLE
Kilian Lommer, Franziska Tutzer, Alex Hofer
We report the case of a 49-year-old male treatment-resistant schizophrenia patient, whose treatment with clozapine and sertraline was supplemented with cariprazine 1.5 mg/day while regularly presenting for electroconvulsive therapy. After 3 weeks of adjunctive treatment with cariprazine, blood tests revealed pronounced signs of rhabdomyolysis, including a creatine kinase serum level of 20 386 U/L and an AST serum level of 696 U/L. Clinically, the patient did not report somatic symptoms other than mild back pain...
December 27, 2023: International Clinical Psychopharmacology
https://read.qxmd.com/read/38100775/direct-to-consumer-advertising-survey-of-psychiatrists-in-massachusetts-and-michigan
#17
JOURNAL ARTICLE
Bennett E Wechsler, Richard Balon, Richard I Shader, Anthony J Rothschild
PURPOSES/BACKGROUND: The goals of this preliminary study were to survey psychiatrists and to examine the impact of advertisements on their prescription of psychotropic medications. The study specifically looked at psychiatrists in Massachusetts and Michigan, as the authors were able to readily contact the members of their respective state psychiatric societies. METHODS/PROCEDURES: We used the survey software, Quatrics, to create an online survey that was sent via email link to the members of the Massachusetts Psychiatric Society (1400 estimated members), and the Michigan Psychiatric Society (700 estimated members)...
January 2024: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/38090698/cariprazine-augmentation-in-patients-with-treatment-resistant-unipolar-depression-who-failed-to-respond-to-previous-atypical-antipsychotic-add-on-a-case-series
#18
JOURNAL ARTICLE
Enrico Pessina, Azzurra Martini, Fabiola Raffone, Vassilis Martiadis
Among individuals receiving an adequate pharmacological treatment for Major Depressive Disorder (MDD), only 30% reach a full symptom recovery; the remaining 70% will experience either a pharmacological response without remission or no response at all thus configuring treatment resistant depression (TRD). After an inadequate response to an antidepressant, possible next step options include optimizing the dose of the current antidepressant, switching to a different antidepressant, combining antidepressants, or augmenting with a non-antidepressant medication...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/38082232/hypersexuality-during-treatment-with-cariprazine-in-a-patient-with-schizophrenia-a-case-report
#19
JOURNAL ARTICLE
Polona Rus Prelog, Anja Kokalj Palandacic
BACKGROUND: Cariprazine is a third-generation antipsychotic with a unique mechanism of action. It functions as a partial agonist with high affinity for dopamine D2 and D3 and serotonin 5-HT1A receptors, an antagonist for 5-HT2A (moderate affinity) and 5-HT2B (high affinity) receptors. It binds to histamine H1 receptors and has a low affinity for 5-HT2C and alpha 1A-adrenergic receptors and no affinity for muscarinic (cholinergic) receptors. Among the troubling side effects, symptoms related to impulse control, such as hypersexuality, pathological gambling, compulsive shopping, compulsive eating etc...
December 11, 2023: BMC Psychiatry
https://read.qxmd.com/read/38041194/the-improvement-of-motor-symptoms-in-huntington-s-disease-during-cariprazine-treatment
#20
JOURNAL ARTICLE
Reka Csehi, Viktor Molnar, Mariann Fedor, Vivien Zsumbera, Agnes Palasti, Karoly Acsai, Zoltan Grosz, Gyorgy Nemeth, Maria Judit Molnar
BACKGROUND: Huntington's disease (HD) is a progressive neurodegenerative disease, characterised by motor disturbances and non-motor (i.e., psychiatric) symptoms. Motor symptoms are the hallmark features of HD and take many forms. Their emergence is related to alterations in striatal dopaminergic neurotransmission: dopamine levels increase in the early stages of the disease, while more advanced stages are characterised by reduced dopamine levels. Such a biphasic change potentially explains the alterations in motor symptoms: increased dopamine-production induces hyperkinetic movements early in the disease course, while depleted dopamine storage leads to hypokinetic symptoms in the advanced phase...
December 1, 2023: Orphanet Journal of Rare Diseases
keyword
keyword
81537
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.